Biliary dysplasia in patients with primary sclerosing cholangitis: additional value of DNA ploidity

Liver Int. 2012 May;32(5):783-9. doi: 10.1111/j.1478-3231.2011.02672.x. Epub 2011 Nov 15.

Abstract

Background: Detection of biliary dysplasia in PSC is essential for proper timing of liver transplantation to prevent the development of cholangiocancer, which is considered a contraindication for liver transplantation in most centres. In patients with PSC, differential diagnosis of benign, premalignant and malignant biliary strictures is difficult.

Aims: This prospective study aimed to evaluate the role of DNA analysis in combination with brush cytology, scored ERCP findings, and tumour markers to detect hepatobiliary dysplasia and malignancy.

Material and methods: Brush samples for cytology and for evaluation of DNA content analysed with flow cytometry came from 102 consecutive PSC patients referred for ERCP. Symptoms, serum Ca19-9 and CEA were determined at the time of index biliary examination. ERCP findings were scored for intra- and extrahepatic changes. The end-points were liver transplantation or diagnosis of malignancy or dysplasia.

Results: Most of the patients were asymptomatic at the time of ERCP: 73% had no symptoms, and 12% had only mild symptoms. An aneuploid DNA content was evident in 20 (20%) patients, and cells suspected for malignancy in 22 (21%). Seven patients had both aneuploidity and cytology (7%) suspicious for malignancy. An end-point, diagnosis of malignancy or liver transplantation was achieved in 42 patients. Combining DNA ploidity and cytology in patients at the end-point, sensitivity was 72%, specificity 82%, positive predictive value 86% and negative predictive value 67%.

Discussion and conclusion: In this mostly asymptomatic PSC-patient population, 33% demonstrated abnormal brush cytology or aneuploidity. Determining DNA ploidy and brush cytology during ERCP offers a useful tool for identifying those PSC patients who are at high risk of developing cholangiocancer.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Biliary Tract Neoplasms / diagnosis
  • Biliary Tract Neoplasms / genetics*
  • Biomarkers, Tumor / blood
  • Biopsy / methods
  • CA-19-9 Antigen / blood
  • Cholangiocarcinoma / diagnosis
  • Cholangiocarcinoma / genetics*
  • Cholangiopancreatography, Endoscopic Retrograde
  • Cholangitis, Sclerosing / complications*
  • DNA, Neoplasm / analysis*
  • Flow Cytometry
  • Humans
  • Ploidies*
  • Prospective Studies

Substances

  • Biomarkers, Tumor
  • CA-19-9 Antigen
  • DNA, Neoplasm